Use of human TNFα antibodies for treatment of erosive polyarthritis

  • US 8,715,664 B2
  • Filed: 05/16/2006
  • Issued: 05/06/2014
  • Est. Priority Date: 05/16/2005
  • Status: Active Grant
First Claim
Patent Images

1. A method for inhibiting radiographic disease progression in a human subject having erosive polyarthritis associated with a disorder in which TNFα

  • activity is detrimental, comprising administering to the subject having erosive polyarthritis an isolated human anti-TNFα

    antibody, or antigen-binding portion thereof, such that radiographic disease progression is inhibited in the subject, wherein a Total Sharp Score (TSS) of the subject is either maintained or decreased following administration of the human anti-TNFα

    antibody, or antigen-binding portion thereof, wherein the human anti-TNFα

    antibody, or an antigen-binding portion thereof, dissociates from human TNFα

    with a Kd of 1×

    10

    8
    M or less and a Koff rate constant of 1×

    10

    3
    s

    1
    or less, both determined by surface plasmon resonance, and neutralizes human TNFα

    cytotoxicity in a standard in vitro L929 assay with an IC50 of 1×

    10

    7
    M or less.

View all claims
    ×
    ×

    Thank you for your feedback

    ×
    ×